M.D., Ph.D., Chief, Division of Oncology, Stanford Medical School
Dr. Levy specializes in lymphoma, including Non-Hodgkin's Lymphoma, Burkitt's Lymphoma and Hodgkin's Disease. His research investigates how the immune system can be harnessed to fight lymphoma. His work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma. His work has been recognized with multiple honors and awards, including the King Faisal International Prize, the Damashek Prize, the American Cancer Society's Medal of Honor, the C. Chester Stock Award from the Memorial Sloan-Kettering Cancer Center, the Karnofsky Award from the American Society of Clinical Oncology, and others.